ImmunityBio has partnered with nCartes to automate and expedite the data fulfilment process for clinical trials, aiming to transform the way data is collected.
The partnership will potentially reduce costs and improve quality for the investigators of ImmunityBio.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The conventional method of data collection in clinical trials involves a manual process where information is collected at research sites and then added to electronic data capture (EDC) systems manually.
This approach is not only slow and costly but also prone to errors, which may lead to delays in the delivery of trial outcomes.
To address this issue, the partnership aims to utilise digital information from source electronic medical record (EMR) systems to directly populate the EDC systems, thereby automating the process.
Anticipated to diminish data entry mistakes, the automation enhances data quality and reduces the time and expenses associated with the verification of the source information.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataImmunityBio CEO and president Richard Adcock said: “ImmunityBio’s innovations in immunotherapies for cancer and infectious diseases depend on getting timely and accurate data from our many ongoing clinical trials.
“The EMR-to-EDC capability nCartes provides will transform this process, reducing delays and enabling us to potentially bring important therapies to market faster.”
nCartes, a provider of cloud software platforms, aims to enable clinical research sponsors and research sites to leverage electronic health systems (EHRs) for automated data capture used in clinical trials and patient registry applications.
nCartes CEO John McIlwain said: “ImmunityBio is doing incredible work with its novel immune system-based therapeutics and vaccines, and has an aggressive clinical trial programme.
“The nCartes team is honoured to have this opportunity to work alongside the ImmunityBio team and their research sites to potentially materially improve the crucial data collection aspect of those trials.”
In August, the company commenced the Phase I/II QUILT 502 clinical trial of ANKTIVA (nogapendekin alfa inbakicept-pmln), in conjunction with the AdHER2DC vaccine, for treating patients with human epidermal growth factor receptor 2 (HER2)-expressing endometrial cancer.
